Zika Virus Antibodies Binding Envelope Protein Fusion Loop
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective countermeasures against Zika virus (ZIKV) as no approved vaccines or therapies exist, and little is known about the virus's structure or biology, making it challenging to develop targeted treatments.
Innovation Solution
Development of antibodies specifically binding to the Zika virus envelope protein, particularly targeting the fusion loop epitope proximal region, using a structure-based computational approach to identify promising scaffolds and mutations in complementarity-determining regions (CDRs) that enhance binding affinity, thereby treating and preventing ZIKV infection, including vertical transmission in pregnant subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are developed to bind Zika virus envelope protein, then prophylactic and therapeutic efficacy is improved, but the complexity of structure-based computational analysis and CDR mutation identification increases
Solution Approach 1:
The antibody variable region is segmented into three complementarity-determining regions (CDR1, CDR2, CDR3) that are independently analyzed and mutated. This segmentation allows systematic identification of specific CDR residues that contribute to binding affinity, reducing the complexity of analyzing the entire antibody structure at once while maintaining the ability to achieve high binding efficacy to the Zika virus envelope protein.
2Strength
If CDR mutations are introduced to enhance binding affinity, then binding strength to Zika virus envelope protein is improved, but the difficulty of identifying favorable contacts and required mutations increases
Solution Approach 1:
The patent replaces traditional experimental methods for identifying favorable antibody-antigen contacts with computational approaches. Molecular dynamics simulations and free energy calculations are used to predict which CDR mutations will enhance binding affinity, substituting computational analysis for labor-intensive experimental screening and making the identification of favorable contacts more systematic and efficient.
3Measurement precision
If structure-based computational approach is used to identify binding scaffolds, then binding specificity to FLEP region is improved, but the loss of time required for computational analysis increases
Solution Approach 1:
The patent performs preliminary computational screening of potential antibody scaffolds and CDR mutations before experimental validation. By using molecular dynamics simulations and free energy calculations to pre-identify promising candidates with high binding specificity to the FLEP region, the approach reduces the number of candidates that require time-consuming experimental testing, thereby reducing overall development time while maintaining high binding specificity.
Data Source
AI summary
Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.